• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Leber Hereditary Optic Neuropathy

Leber Hereditary Optic Neuropathy - 21 Studies Found

Completed : Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy
: Leber Hereditary Optic Neuropathy
: 2014-06-25
: Drug: cyclosporine
Withdrawn : Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
: Leber's Hereditary Optic Neuropathy
: 2011-12-16
:
  • Drug: Idebenone
  • Drug: Placebo

Completed : Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
: Leber Hereditary Optic Neuropathy (LHON)
: 2013-06-26
Recruiting : Post Authorisation Safety Study With Raxone in LHON Patients
: Leber's Hereditary Optic Neuropathy (LHON)
: 2016-04-25
: Drug: Idebenone Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
Recruiting : Study to Assess the Efficacy and Safety of Raxone in LHON Patients
: Leber's Hereditary Optic Neuropathy (LHON)
: 2016-05-12
: Drug: Idebenone Other Name: Raxone
Completed : A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)
: Optic Atrophy, Hereditary, Leber
: 2007-09-11
: Drug: curcumin curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the seco
Completed : Biomechanics of Optic Neuropathy
: Optic Neuropathy
: 2016-08-28
: Device: magnetic resonance image (MRI)
Active, not recruiting : Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation
: Optic, Atrophy, Hereditary, Leber
: 2016-01-07
:
  • Genetic: GS010

Completed : Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation
: Optic, Atrophy, Hereditary, Leber
: 2016-01-07
:
  • Genetic: GS010

Completed : Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
: Leber Hereditary Optic Neuropathy (LHON)
: 2025-07-31
: The starting dose is 1.5�108 vg, 0.05 mL eye/dose.If drug-related dose-limiting toxicity (DLT) events are observed in < 2 of the 6 evalu
<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.